Panel Discusses Opportunity Costs, Innovative Drugs
May 22, 2020
A recent panel during Virtual ISPOR 2020 discussed how payers grapple with opportunity costs as innovative therapies hit the market.
AJMC in an article outlines the discussion that was moderated by Mark Sculpher, professor of health economics at York University.
“Those opportunity costs could include budget constraints on spending on social determinants of health, such as housing, education, or job training, or preventive public health and primary care that could reduce the need for high-cost therapeutic services or technologies in the first place,” the article states.
To read the full report on AJMC, click here.
